Adial Pharmaceuticals is dedicated to finding medicinal solutions for Alcohol Use Disorder (AUD). As a part of our efforts, we are conducting a survey to better understand the habits and issues surrounding the use of alcohol and need your help. No identification information will be collected, so your response will be anonymous.
Adial is preparing to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.